Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
1.
Rev Med Liege ; 75(4): 265-270, 2020 Apr.
Article in French | MEDLINE | ID: mdl-32267117

ABSTRACT

The goal of the article was to provide some clinical recommendations for a secure use of lithium. We described the mechanism of action of lithium, that acts as a mood stabilizer but also has anti-suicidal and neuroprotective effects. We also described the toxics effects of lithium and the toxicological tools that help to prevent and to treat those effects. We concluded that lithium remains a first choice for the treatment of bipolar disorders.


L'article fournit des recommandations cliniques pour utiliser le lithium de façon efficace et sûre. Nous décrivons les mécanismes d'action du lithium, stabilisateur de l'humeur aux propriétés antisuicidaires et neuroprotectrices. Nous détaillons les effets toxiques du lithium et les outils de toxicologie clinique qui permettent de les prévenir et de les diagnostiquer. Le lithium reste le traitement de référence des troubles bipolaires.


Subject(s)
Bipolar Disorder , Lithium/adverse effects , Psychotropic Drugs , Bipolar Disorder/drug therapy , Humans , Psychotropic Drugs/adverse effects , Risk Assessment
2.
QJM ; 112(7): 519-522, 2019 Jul 01.
Article in English | MEDLINE | ID: mdl-30895319

ABSTRACT

BACKGROUND: Pneumothorax is one of the respiratory toxic effects of cocaine inhalation. The literature counts several cases, some associated to other respiratory conditions such as pneumomediastinum, haemoptysis and others not requiring surgical treatment. AIM: We present a series of nonHIV cocaine-inhaler subjects who underwent video-assisted thoracoscopic surgery (VATS) for isolated spontaneous pneumothorax. DESIGN: Nine subjects, with a mean age of 24 ± 4 years, admitting cocaine inhalation, developed spontaneous pneumothorax and underwent 10 surgical treatments by means of VATS, at our Institution. RESULTS: Previous pneumothorax occurred in six cases episodes ranged from 0 to 5 (mean 1.6 ± 1.6). Chest computed tomography (CT) scan showed abnormalities in seven cases. All subjects underwent lung apicectomy, apical pleurectomy and mechanical pleurodesis. Seven subjects had also bullectomy. In all cases the visceral pleura was partially covered by fibrinous exudate. Histology of the lung showed small foreign body granulomatous inflammation in fibrotic and/or emphysematous pulmonary parenchyma. Relapse of pneumothorax occurred in one subject at 60 days and it was surgically treated. Mean follow-up was 150 ± 38 months (range 120-239). All subjects are now well, with no evidence of pneumothorax. CONCLUSIONS: Spontaneous pneumothorax in cocaine-inhaler subjects is a reality of which physicians need to be aware. Chest CT scan might not reveal abnormalities. Macroscopically the lung might presents bullae and/or peculiar visceral pleura. Foreign body granulomas observed in the specimens suggest that the particulate component of inhaled substances can injure the lung. Surgical treatment of the bullous disease and mechanical pleurodesis can provide a long-term follow-up without relapse of pneumothorax.


Subject(s)
Cocaine-Related Disorders/complications , Cocaine/adverse effects , Pneumothorax/surgery , Thoracic Surgery, Video-Assisted , Administration, Inhalation , Adult , Cocaine/administration & dosage , Cocaine-Related Disorders/diagnosis , Female , Foreign Bodies/complications , Foreign Bodies/diagnosis , Foreign Bodies/pathology , Humans , Italy , Male , Pneumothorax/etiology , Recurrence , Retrospective Studies , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
3.
Ann Ig ; 20(6): 553-62, 2008.
Article in Italian | MEDLINE | ID: mdl-19238880

ABSTRACT

Aim of this survey is to identify those filamentous fungi which parasite Boletus edulis and its group and check the potential presence of secondary metabolites, specifically aflatoxin B1, total aflatoxins and ochratoxin A, in order to assess the risk to consumers' health. Forty samples of dried Boletus edulis, collected by two food industries which distribute the product in many Italian regions, have been analysed. The sampling plan has been conducted from November 2005 to March 2006, collecting 50 g from each commercial category of dried Boletus edulis available in the factory at the time of sampling. All the samples have been tested by visual macroscopic and stereoscopic assays; for some samples--those referred to commercial category presumably at higher risk--we have performed cultural assays as well, typization of isolated micromycetes, extraction and quantification of aflatoxins and ochratoxin A. Mycotoxin detection has been made by HPLC, using the UNI EN 14123 and UNI EN 14132 standard methods, respectively applied to aflatoxins determination in peanuts, pistachios, figs and paprika and to ochratoxin A in barley and coffee. Non pathogenic micromycetes, common in food products, have been frequently observed in cultural assays, while Aspergillus flavus and Aspergillus niger have been found in some samples. However the concentration of aflatoxins was always under the quantification limit. The survey confirm that, if the cold chain is kept throughout the process and the distribution, Boletus edulis and analogue mycetes are not a favourable substratum for the growth and the development of moulds.


Subject(s)
Aflatoxins/analysis , Agaricales/chemistry , Carcinogens/analysis , Ochratoxins/analysis , Poisons/analysis , Aflatoxin B1/analysis , Aspergillus flavus/chemistry , Aspergillus niger/chemistry , Chromatography, Thin Layer , Consumer Product Safety , Desiccation , Food Contamination/analysis , Food Contamination/legislation & jurisprudence , Health Surveys , Humans , Italy , Legislation, Food , Mitosporic Fungi/chemistry , Quality Control
4.
J Control Release ; 111(1-2): 219-27, 2006 Mar 10.
Article in English | MEDLINE | ID: mdl-16458987

ABSTRACT

The pharmaceutical utility of silk fibroin (SF) materials for drug delivery was investigated. SF films were prepared from aqueous solutions of the fibroin protein polymer and crystallinity was induced and controlled by methanol treatment. Dextrans of different molecular weights, as well as proteins, were physically entrapped into the drug delivery device during processing into films. Drug release kinetics were evaluated as a function of dextran molecular weight, and film crystallinity. Treatment with methanol resulted in an increase in beta-sheet structure, an increase in crystallinity and an increase in film surface hydrophobicity determined by FTIR, X-ray and contact angle techniques, respectively. The increase in crystallinity resulted in the sustained release of dextrans of molecular weights ranging from 4 to 40 kDa, whereas for less crystalline films sustained release was confined to the 40 kDa dextran. Protein release from the films was studied with horseradish peroxidase (HRP) and lysozyme (Lys) as model compounds. Enzyme release from the less crystalline films resulted in a biphasic release pattern, characterized by an initial release within the first 36 h, followed by a lag phase and continuous release between days 3 and 11. No initial burst was observed for films with higher crystallinity and subsequent release patterns followed linear kinetics for HRP, or no substantial release for Lys. In conclusion, SF is an interesting polymer for drug delivery of polysaccharides and bioactive proteins due to the controllable level of crystallinity and the ability to process the biomaterial in biocompatible fashion under ambient conditions to avoid damage to labile compounds to be delivered.


Subject(s)
Delayed-Action Preparations/chemistry , Fibroins/chemistry , Polymers/chemistry , Adsorption , Animals , Bombyx/chemistry , Chromatography, High Pressure Liquid , Crystallization , Delayed-Action Preparations/pharmacokinetics , Dextrans/chemistry , Dextrans/pharmacokinetics , Fibroins/isolation & purification , Fluorescence , Horseradish Peroxidase/chemistry , Horseradish Peroxidase/pharmacokinetics , Methanol/chemistry , Microscopy, Atomic Force , Molecular Weight , Muramidase/chemistry , Muramidase/pharmacokinetics , Spectroscopy, Fourier Transform Infrared , Surface Properties , Technology, Pharmaceutical/methods , Time Factors
5.
Haematologica ; 85(1): 63-6, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10629594

ABSTRACT

BACKGROUND AND OBJECTIVE: Chronic hepatitis C was a frequent complication in patients treated for malignancy until the introduction of anti-HCV screening tests for blood donors. The association between chronic hepatitis C and progression to cirrhosis and hepatocellular carcinoma has been reported in about 20% and 5% of patients, respectively, within 20-30 years of infection. In adult patients, interferon has proved to be effective in decreasing the abnormal values of transaminases and the level of HCV viremia. Our purpose was to assess efficacy of and tolerance to interferon in a group of young patients who had acquired HCV infection during a period of chemotherapy. DESIGN AND METHODS: Interferon-a (IFN) was administered to 26 adolescents and young adults (13 males, age range 17-36 years; median age 24) with chronic hepatitis C, including 4 with hepatitis B virus co-infection, who had been treated for leukemia or solid tumor 5 to 19 years before joining this trial. Patients were treated with natural IFN alpha at a dose of 4 MU/m(2) thrice weekly for 12 months and followed up for another 6 months thereafter. RESULTS: Nine patients stopped treatment during the first 6 months because of side effects (2 cases) or lack of response. At the end of the trial, 8 (31%) cases had responded, with alanine amino-transferase normalization and clearance of hepatitis C virus (HCV) RNA. A sustained response was only documented in 15% of cases, however, irrespective of any hepatitis B virus co-infection. The 2 patients with HCV genotype 2 were both responders, whereas only 8% of those with genotype 1 responded. INTERPRETATION AND CONCLUSIONS: These data show that the efficacy of IFN in this series of young patients is similar to that reported for otherwise healthy adults with hepatitis C. Patients with genotype 2 are strong candidates for IFN treatment while other therapeutic strategies should be designed for patients with HCV genotype 1.


Subject(s)
Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Interferon-alpha/toxicity , Acetaminophen/administration & dosage , Adolescent , Adult , Alanine Transaminase/blood , Alopecia/chemically induced , Asthenia/chemically induced , Chlorpheniramine/administration & dosage , DNA, Viral/blood , Female , Fever/chemically induced , Hepatitis B/blood , Hepatitis B Surface Antigens/blood , Hepatitis B e Antigens/blood , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/etiology , Humans , Male , Neoplasms/complications , Neutropenia/chemically induced , Purpura, Thrombocytopenic, Idiopathic/chemically induced , RNA, Viral/blood , Risk Factors , Transfusion Reaction
6.
Bone Marrow Transplant ; 24(1): 47-51, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10435734

ABSTRACT

Thrombotic microangiopathy (TMA) usually occurs during the first weeks following transplantation in the setting of systemic infections or graft-versus-host reaction. However, some cases without any evidence of other complications or after autologous transplantation have been reported. Transplant-associated TMA (BMT-TMA) incidence ranges from 0% to 74%, possibly due to different diagnostic criteria. The GITMO Group provided the opportunity to retrospectively study 4334 consecutive Italian patients who received bone marrow transplants (1759 allogeneic and 2575 autologous BMT), during the 1985-1995 period. The present report focuses on patients with severe TMA requiring specific treatment. We identified nine cases of TMA as a complication of allogeneic BMT (0.51%), whereas three patients developed the syndrome after ABMT (0.13%); four of the 12 patients were not receiving CsA at the time of TMA onset. Finally, it is noteworthy that TMA occurred in seven patients as a late complication (up to 90 days after BMT). Despite intensive treatment, five of the seven patients with thrombotic thrombocytopenic purpura died. One death was observed among the five cases with hemolytic uremic syndrome.


Subject(s)
Bone Marrow Transplantation/adverse effects , Thrombosis/complications , Thrombosis/epidemiology , Adult , Child , Child, Preschool , Female , Humans , Male , Microcirculation/drug effects , Microcirculation/pathology , Retrospective Studies , Severity of Illness Index , Surveys and Questionnaires , Thrombosis/drug therapy , Thrombosis/pathology , Transplantation, Autologous/adverse effects , Transplantation, Homologous/adverse effects , Treatment Outcome
7.
Bone Marrow Transplant ; 21(10): 1015-21, 1998 May.
Article in English | MEDLINE | ID: mdl-9632275

ABSTRACT

From January 1984 to December 1994, ABMT was performed on 154 children (101 males, 53 females; median age 10, range 3-21 years) with ALL and registered for BMT by the AIEOP (Italian Association of Paediatric Haemato-Oncology). All patients were in CR: 98 were in 2nd CR and 56 were in >2nd CR. Fifteen children (9.7%) died of transplant-related mortality. Ninety-five patients (61.6%) relapsed at a median of 5 (range 1-42) months after ABMT. The 8-year EFS according to pre-BMT status was 34.6% (s.e. 4.9) for 2nd CR patients and 10.6% (s.e. 5.6) for patients in >2nd CR. By univariate analysis, site of relapse (isolated extramedullary (IE) vs BM: EFS = 68.5% vs 18.2%; P < 0.0001) and TBI containing regimen (TBI vs no TBI: EFS = 48.1 vs 15.4%; P = 0.0023) were significant factors for 2nd CR patients. When the 2nd CR subset with BM involvement was analysed, TBI became insignificant (EFS = 25.4 vs 11.8%). No factors influenced EFS in patients in >2nd CR. By multivariate analysis, site of relapse was the only significant factor in 2nd CR patients (P < 0.0001). In conclusion, ABMT is an effective treatment after one early IE relapse. Few patients can be rescued after BM relapse.


Subject(s)
Bone Marrow Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Retrospective Studies , Transplantation, Autologous
8.
J Orthop Res ; 16(1): 89-95, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9565078

ABSTRACT

The capacity of isolated chondrocytes to join separate masses of cartilage matrix was investigated with composites implanted in subcutaneous pouches in nude mice. Slices of articular cartilage were harvested from lambs and were devitalized by cyclic freezing and thawing. The slices were then either co-cultured with viable allogeneic lamb chondrocytes (experimental) or cultured without such chondrocytes (control). Composites of three slices were constructed with use of fibrin glue and were implanted in nude mice for periods ranging from 7 to 42 days. Bonding of the experimental matrices with viable chondrocytes was achieved at 28 and 42 days, as assessed by direct examination, histology, thymidine uptake, and fluorescence. No bonding occurred in the control composites without viable chondrocytes. We conclude that devitalized cartilage matrix is a scaffold to which isolated chondrocytes can attach and begin to repopulate.


Subject(s)
Cartilage/cytology , Chondrocytes/physiology , Animals , Cells, Cultured , Fibrin Tissue Adhesive , Mice , Sheep , Thymidine/metabolism
9.
Bone Marrow Transplant ; 21(1): 9-14, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9486488

ABSTRACT

The purpose of this study was to assess the role of ABMT in children with ALL who are in 2nd CR after an early isolated CNS relapse. All children experiencing an isolated CNS relapse at 10 AIEOP centers (Associazione Italiana Emato-Oncologia Pediatrica) from 1986 to 1992 were eligible for this study. The series included 69 patients who relapsed within 3 years from diagnosis: 19 underwent ABMT, nine patients underwent ALLO-BMT from an HLA-identical sibling, and 41 received conventional chemotherapy (CHEMO). Statistical analysis was performed using a Cox's regression model, adjusting for the waiting time before transplantation and prognostic factors. The 5 years DFS was 56.3% (s.e. 12.3) for patients in the ABMT group. This compared favorably with the poor result (12.6% (s.e. 5.9)) seen in the CHEMO group. The risk of failures was reduced by one-third in the ABMT group as compared to the CHEMO group in the multivariate analysis (P < 0.01). In the ALLO group four out of nine patients were in CCR 4-5 years post-transplant. This study suggests that ABMT may also represent a valuable therapeutic choice for patients lacking a matched familiar donor in 2nd CR after an early isolated CNS relapse.


Subject(s)
Bone Marrow Transplantation , Meningeal Neoplasms/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Infant, Newborn , Male , Meningeal Neoplasms/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Recurrence , Transplantation, Autologous
10.
Blood ; 90(3): 1315-20, 1997 Aug 01.
Article in English | MEDLINE | ID: mdl-9242567

ABSTRACT

Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.


Subject(s)
Hepatitis C/epidemiology , Hepatitis, Chronic/epidemiology , Neoplasms/complications , Adolescent , Adult , Alanine Transaminase/blood , Biomarkers , Biopsy , Child , Female , Follow-Up Studies , Hepatitis Antibodies/blood , Hepatitis B/enzymology , Hepatitis B/epidemiology , Hepatitis B/transmission , Hepatitis C/complications , Hepatitis C/diagnosis , Hepatitis C/enzymology , Hepatitis C/transmission , Hepatitis D/enzymology , Hepatitis D/epidemiology , Hepatitis D/transmission , Hepatitis Delta Virus/immunology , Hepatitis Viruses/immunology , Hepatitis Viruses/isolation & purification , Hepatitis, Chronic/complications , Hepatitis, Chronic/diagnosis , Hepatitis, Chronic/enzymology , Humans , Liver/pathology , Liver Failure/epidemiology , Liver Failure/etiology , Male , Neoplasms/therapy , Prevalence , RNA, Viral/blood , Risk Factors , Transfusion Reaction
11.
Br J Haematol ; 97(4): 848-54, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9217188

ABSTRACT

Photopheresis (ECP) is a new type of photochemotherapy, used for the treatment of oncological and autoimmune diseases. Lymphocytes are drawn from the patients by leukapheresis, treated with 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) in an extracorporeal system and then reinfused. Skin exposure to 8-MOP and UVA (PUVA) has been shown to relieve cutaneous symptoms of graft-versus-host disease (GVHD) in bone marrow transplant (BMT) recipients. ECP, which is similar in some ways to PUVA, has been used in this study to treat four paediatric patients who developed chronic GVHD following BMT and in whom GVHD had failed to respond to conventional immunosuppressive therapy. Following ECP, skin lesions cleared almost completely and pulmonary function tests improved in two of three patients with cutaneous and lung involvement. Serum bilirubin and transaminases gradually normalized, and gammaGT decreased considerably in the remaining patient who had a severe cholestatic hepatopathy. The Karnofsky performance score increased to 90% in the three patients with positive responses to ECP and remained unchanged (40%) in the patient who did not respond. Immunosuppressive therapy was reduced in three patients and eventually discontinued in two. No significant side-effects were observed during the treatment. Our results suggest that ECP is a non-aggressive treatment that may benefit patients with chronic GVHD who do not respond to standard immunosuppressive therapy.


Subject(s)
Graft vs Host Disease/drug therapy , Photopheresis/methods , Adolescent , Bone Marrow Transplantation , Child , Chronic Disease , Drug Resistance , Humans , Male , Photopheresis/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
12.
Bone Marrow Transplant ; 18 Suppl 2: 40-2, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8932797

ABSTRACT

The role of autologous bone marrow transplantation (ABMT) in childhood ALL after an isolated extramedullary (IE) relapse is controversial. Between December 1984 and November 1995, 52 children underwent ABMT because of an IE relapse. The data were stored in the AIEOP-BMT Registry. Thirty four children were transplanted in 2nd CR; eighteen > 2nd CR. The median duration of 1st CR was 24 (range 3-69) and 18 (range 3-59) months, respectively. The median interval from last CR to ABMT was 6 (range 1-28) and 3 (range 1-81) months, respectively. The 5 year EFS for patients transplanted in 2nd CR was 67.7%, while the 3 year EFS for patients in > 2nd CR was 16.7%. In conclusion, ABMT was an effective treatment in early IE relapse only if performed in 2nd CR.


Subject(s)
Bone Marrow Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Recurrence , Transplantation, Autologous , Treatment Outcome
13.
Bone Marrow Transplant ; 18 Suppl 2: 59-62, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8932801

ABSTRACT

This report summarizes indications and results of autologous bone marrow transplantation (ABMT) performed in childhood acute myeloid leukemia (AML) in Italy since 1984. A total of 158 patients have been reported from 12 teams to the AIEOP-BMT Registry: 110 have been autografted in first complete remission (CR) and 48 in second remission. Several conditioning regimens have been utilized, mainly consisting of BAVC (an original polichemotherapy schedule, BCNU, mAMSA, VP-16 and Ara-C) (63 cases) and of total body irradiation (TBI) plus Melphalan (33 cases): other 28 patients received different TBI-including regimens, and 34 received various chemotherapy regimens (Busulfan plus cyclophosphamide +/- VP-16, Busulfan plus Melphalan, Melphalan alone). Projected event-free survival (EFS) for patients autografted in first CR is 41.4% (S.E. 5.5%) at 7 years, with a total of 53 patients in continuous CR. EFS is better in patients receiving a TBI-including regimen: 78.8% versus 27.2% (p = 0.0001). In particular, results obtained in a subgroup of 21 cases receiving TBI + melphalan and purged marrow are particularly encouraging, with a EFS > 85% projected a 7 years. The overall EFS in second CR is 41.5% at 7 years, and no difference have been observed after a TBI-including regimen or after a chemotherapy regimen, being EFS 43.1% and 39.3% for these 2 groups respectively. A total of 11 transplant-related deaths occurred, with 5 patients (4.5%) dead in first CR and 6 (12%) dead in second CR within 100 days from transplant. From these data, ABMT is confirmed to represent an effective treatment for AML after first relapse, while the encouraging results obtained in first CR with TBI-including regimens should be confirmed with a longer follow up and a larger number of patients.


Subject(s)
Bone Marrow Transplantation , Leukemia, Myeloid, Acute/therapy , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Italy , Male , Transplantation, Autologous , Treatment Outcome
16.
Bone Marrow Transplant ; 18 Suppl 2: 175-81, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8932825

ABSTRACT

Photopheresis is an extracorporeal photochemotherapy (ECP) used for the treatment of oncological and autoimmune diseases. Lymphocytes are drawn from the patients by leukapheresis, treated with 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) in an extracorporeal system; then, reinfused to the host. Because skin exposure to 8-MOP and UVA (PUVA) has been shown to improve cutaneous GVHD, we evaluated in a pilot study, if ECP might be beneficial for patients with GVHD unresponsive to conventional protocols. In this study, we enrolled 9 children or young adults, with acute (no = 1) or chronic extensive GVHD (no. = 8). A significant improvement was observed in three of the 5 patients with scleroderma-like lesions and in one patient with severe liver involvement. Karnofsky performance score improved from 30-50% to 90% in the 4 responders. The better control of GVHD in these patients allowed a reduction of the immunosuppressive therapy that was, finally, discontinued in two. No significant side effects were observed during ECP. Our results suggest that ECP is a nonaggressive treatment that may benefit patients with c-GVHD unresponsive to standard immunosuppressive therapies.


Subject(s)
Graft vs Host Disease/drug therapy , PUVA Therapy , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Treatment Outcome
17.
Bone Marrow Transplant ; 18(1): 125-30, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8832005

ABSTRACT

This study reports a large cooperative experience in myeloablative therapy and bone marrow rescue undertaken to define better the outcome of children with disseminated neuroblastoma after megatherapy. Between 1984 and 1993, 135 children underwent myeloablative therapy with bone marrow transplantation (BMT) in nine Italian Centres. One hundred and seventeen children received unpurged autologous BMT, five allogeneic BMT and 13 peripheral blood progenitor cells as rescue. Of these 135 children, 57 were in 1st CR, 11 in 2nd or subsequent CR, 42 in 1st PR, and 25 had more advanced disease. Twelve children (9%) died of toxicity, 86 relapsed or progressed at 1-68 months (median 7 months) and 80 of these subsequently died of progressive disease. Forty-three children are still alive with 37 in continuous remission at a median of 65 months (30-123 months) after BMT. Overall and disease-free survival at 8 years are 28.5% (s.e. 4.3) and 26% (s.e. 4), respectively. Disease-free survival is 34.6% (s.e. 6.7) for the patients grafted in 1st complete remission, 23.6% (s.e. 6.6) for patients grafted in 1st partial remission, 36.4% (s.e. 14.5) for patients grafted in 2nd or subsequent CR, and 8% (5.4) for patients with advanced disease. We conclude these data confirm that early toxicity of myeloablative therapy is manageable and that myeloablative therapy with bone marrow rescue may contribute to an improved long-term survival of children with disseminated neuroblastoma but the objective of cure of all patients remains distant.


Subject(s)
Bone Marrow Transplantation , Neuroblastoma/therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation/statistics & numerical data , Chemical and Drug Induced Liver Injury , Child , Child, Preschool , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Infant , Infant, Newborn , Infections/etiology , Infections/mortality , Italy/epidemiology , Liver Diseases/mortality , Male , Melphalan/administration & dosage , Neuroblastoma/drug therapy , Neuroblastoma/mortality , Neuroblastoma/pathology , Neuroblastoma/radiotherapy , Registries , Survival Analysis , Survival Rate , Transplantation Conditioning/adverse effects , Treatment Outcome , Vincristine/administration & dosage , Whole-Body Irradiation/adverse effects
18.
Bone Marrow Transplant ; 17(5): 729-35, 1996 May.
Article in English | MEDLINE | ID: mdl-8733689

ABSTRACT

The role of ABMT in the treatment of acute leukemia patients with poor prognosis is controversial because of the high risk of relapse. We attempted to obtain an anti-tumor effect by administering rIL-2 pre- and/or post-ABMT. We report our experience in 10 consecutive pediatric patients: two AML late responders and eight ALL in 2nd or subsequent CR who received ABMT and rIL-2. Five patients (group A) received rIL-2 only post-ABMT. A 120 h/week rIL-2 'induction' cycle at 6 x 10(6) IU/m2/24 h was administered by continuous intravenous infusion for 2 weeks. A further six maintenance rIL-2 cycles at 18 x 10(6) IU/m2/24 h were given 72 h/week on a monthly basis. Five patients (group B) received a single 120 h cycle of rIL-2 at 6 x 10(6)/m2/24 h before BM harvesting. Three of the five group B patients entered the same protocol described above after ABMT. Increased NK and LAK activity were documented. The cycles were well tolerated; no delayed engraftment in group B was observed. One patient in group A and two patients in group B are still in CCR, respectively 47, 42 and 15 months after ABMT. Our rIL-2 regimen; pre- and/or post-ABMT, was safely tolerated and induced significant immunomodulatory effects in pediatric patients


Subject(s)
Bone Marrow Transplantation , Interleukin-2/administration & dosage , Leukemia, Myeloid, Acute/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Adult , Child , Child, Preschool , Combined Modality Therapy , Female , Humans , Killer Cells, Lymphokine-Activated/immunology , Killer Cells, Natural/immunology , Leukemia, Myeloid, Acute/immunology , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Recombinant Proteins/administration & dosage , Transplantation, Autologous
19.
Bone Marrow Transplant ; 17(1): 55-62, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8673056

ABSTRACT

From 1 September 1988 to 30 September 1993, a search for an unrelated donor (URD) was started for 633 Italian patients. Eighty-five of them (13%) were transplanted. Despite the introduction of more strict criteria for the selection of compatible donors, the percentage of patients who reached transplant increased significantly after December 1992. For patients who started a search before and after January 1993, respectively the probability of transplant by 8 and 16 months from search activation was 4 and 10%, compared to 22 and 37% (P = 0.0001). The average intervals between search activation and graft were 15 and 8 months respectively, for the first and second group (P = 0.0001). Data of 75 consecutive transplants performed up to March 1994 were analyzed. Actuarial 2-year survival was 15% for patients grafted before 1992 and 40% for those grafted after January 1992. In this latter period, survival of patients with malignant and non-malignant disorders was 32 and 67%, respectively. In univariate analysis, patients younger than 16 years (P = 0.01), patients grafted after 1992 (P = 0.01) and patients receiving the marrow from a 6-antigen matched donor (P = 0.01) showed a higher survival probability. Multivariate analysis did not show any difference, probably due to the low number of patients and to short follow-up. The adoption of stricter and more accurate HLA-matching criteria and the consequent reduction of deaths related to acute GVHD were the main reasons for the improvement of survival observed in patients grafted after 1992.


Subject(s)
Bone Marrow Transplantation , Adolescent , Adult , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/mortality , Child , Child, Preschool , Female , Graft vs Host Disease/etiology , Histocompatibility Testing , Humans , Infant , Infant, Newborn , Male , Middle Aged , Recurrence , Survival Rate , Tissue Donors
20.
Appl Opt ; 35(18): 3185-92, 1996 Jun 20.
Article in English | MEDLINE | ID: mdl-21102698

ABSTRACT

We present the numerical and experimental study that we carried out to compare the performances of two hybrid stable-unstable resonators for diffusion-cooled CO(2) slab lasers. The two resonators are designed to fit a 320 mm × 60 mm ×2 mm rf-discharge channel and are both guided in the narrow transverse direction. They differ in the other transverse direction, consisting of a positive- or a negative-branch unstable resonator scheme. The two solutions have been characterized in terms of modal structure, power extraction, stability, and quality of the extracted beam.

SELECTION OF CITATIONS
SEARCH DETAIL
...